Institutional members access full text with Ovid®

First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants

Hurwitz, Julia La,b,d; Lockey, Timothy Da,c; Jones, Barta,b; Freiden, Pamelab; Sealy, Roberta,b; Coleman, Johnc; Howlett, Nannab; Branum, Kristenb; Slobod, Karen Sb,e

doi: 10.1097/QAD.0b013e3282f174ed
Research Letters

To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.

aDepartment of Immunology, St Jude Children's Research Hospital, Memphis, Tennessee, USA

bDepartment of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA

cDepartment of Therapeutics, Production and Quality, St Jude Children's Research Hospital, Memphis, Tennessee, USA

dDepartment of Pathology, University of Tennessee, Memphis, Tennessee, USA

eDepartment of Pediatrics, Health Science Center, University of Tennessee, Memphis, Tennessee, USA.

Received 19 July, 2007

Accepted 22 August, 2007

© 2008 Lippincott Williams & Wilkins, Inc.